Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay

This report describes the process of making an immunoassay based on commercially available reagents “clinically ready”. The assay was developed to quantify poly(ADP-ribose) (PAR) levels as a marker of PAR polymerase inhibitor activity for a proof-of-concept phase 0 clinical trial at the National Cancer Institute (NCI) and subsequent clinical trials.

Source: Seminars in Oncology - June 13, 2016 Category: Cancer & Oncology Authors: Katherine V. Ferry-Galow, Jiuping Ji, Robert Kinders, Yiping Zhang, R. Kenneth Czambel, John C. Schmitz, Josef Herzog, Yvonne A. Evrard, Ralph Parchment Source Type: research